Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1316
Title: Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit?
Authors: Sturm, Jonathan ;Gilligan, A.K.;Thrift, A.G.;Dewey, H.M.;Macdonell, R.A.;Donnan, G.A.
Issue Date: 2005
Source: Volume 20, Issue 4, pp. 239 - 244
Journal title: Cerebrovascular Diseases
Abstract: BACKGROUND: Although a number of acute stroke interventions are of proven efficacy, there is uncertainty about their community benefits. We aimed to assess this within a defined population. METHODS: Eligibility for tissue plasminogen activator (tPA), aspirin, stroke unit management and neuroprotection were assessed among incident stroke cases within the community-based North East Melbourne Stroke Incidence Study. RESULTS: Among 306,631 people, there were 645 incident strokes managed in hospital. When eligible patients were extrapolated to the Australian population, for every 1,000 cases, 46 (95% CI 17-69) could have been saved from death or dependency with stroke unit management, 6 (95% CI 1-11) by using aspirin, 11 (95% CI 5-17) or 10 (95% CI 3-16) by using tPA at 3 and 6 h, respectively. CONCLUSIONS: Although tPA is the most potent intervention, management in stroke units has the greatest population benefit and should be a priority.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1316
DOI: 10.1159/000087705
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/16123543
ISSN: 1015-9770
Publicaton type: Journal Article
Keywords: Neurology
Stroke
Appears in Collections:Neurology

Show full item record

Page view(s)

48
checked on Oct 11, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.